We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+4.62%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$115M
AUM Growth
-$7.74M
Cap. Flow
-$373K
Cap. Flow %
-0.32%
Top 10 Hldgs %
66.12%
Holding
72
New
4
Increased
20
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$963K
2
SLDB icon
Solid Biosciences
SLDB
+$551K
3
KIDS icon
OrthoPediatrics
KIDS
+$494K
4
XENE icon
Xenon Pharmaceuticals
XENE
+$418K
5
PRTA icon
Prothena Corp
PRTA
+$402K

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1.36M
2
UTHR icon
United Therapeutics
UTHR
+$857K
3
MASI
Masimo
MASI
+$694K
4
AXGN icon
Axogen
AXGN
+$650K
5
CORT icon
Corcept Therapeutics
CORT
+$487K

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Energy 3.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXDX
51
DELISTED
Accelerate Diagnostics
AXDX
$228K 0.2%
325,239
– –
ARVN icon
52
Arvinas
ARVN
$517M
$211K 0.18%
30,000
+15,000
+100% +$235K
NPCE icon
53
Neuropace
NPCE
$537M
$202K 0.18%
16,442
+6,442
+64% +$80.6K
TELA icon
54
TELA Bio
TELA
$32.2M
$189K 0.16%
155,000
+30,000
+24% +$73.8K
KROS icon
55
Keros Therapeutics
KROS
$210M
$153K 0.13%
15,000
– –
GOSS icon
56
Gossamer Bio
GOSS
$68.9M
$152K 0.13%
138,176
– –
CGEM icon
57
Cullinan Oncology
CGEM
$1.08B
$151K 0.13%
20,000
– –
LQDA icon
58
Liquidia Corp
LQDA
$6.85B
$148K 0.13%
10,013
+13
+0.1% +$190
TECL icon
59
Direxion Daily Technology Bull 3x ETF
TECL
$5.17B
$144K 0.13%
20,000
+2,000
+11% +$163K
ATRA icon
60
Atara Biotherapeutics
ATRA
$74.7M
$131K 0.11%
22,000
– –
ZBIO
61
Zenas BioPharma
ZBIO
$1.94B
$130K 0.11%
16,500
– –
KPTI icon
62
Karyopharm Therapeutics
KPTI
$169M
$105K 0.09%
27,985
-4
-0% -$34
TSVT
63
DELISTED
2seventy bio
TSVT
$76.6K 0.07%
15,500
-333
-2% -$1.06K
ALMS
64
Alumis Inc
ALMS
$3.57B
$61.4K 0.05%
10,000
– –
IFRX icon
65
InflaRx
IFRX
$268M
$51K 0.04%
50,000
– –
CMPX icon
66
Compass Therapeutics
CMPX
$364M
$45.6K 0.04%
+24,000
New +$63.8K
VTYX
67
DELISTED
Ventyx Biosciences
VTYX
$33.1K 0.03%
28,800
– –
ZNTL icon
68
Zentalis Pharmaceuticals
ZNTL
$357M
$27K 0.02%
17,000
– –
CHRS icon
69
Coherus Oncology
CHRS
$219M
– –
-82,000
Closed -$113K
SRPT icon
70
Sarepta Therapeutics
SRPT
$1.78B
– –
-3,500
Closed -$426K
CERO
71
DELISTED
CERo Therapeutics
CERO
– –
-6
Closed -$778
BHVN
72
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-7,365
Closed -$275K
1 2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Birchview Capital held 72 positions worth $115M, down 6.3% from $123M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Birchview Capital's Q1 2025 filing shows 4 new, 20 increased, 11 reduced and 4 closed positions. Its largest new stake was Solid Biosciences: 128,768 shares worth $476K. The largest sale was Acadia Pharmaceuticals, an estimated $1.36M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy.

  • Birchview Capital's largest Q1 2025 buy was Solid Biosciences: 128,768 shares worth $476K.
  • Birchview Capital added most to uniQure in Q1 2025, an estimated $963K increase.
  • Birchview Capital's biggest Q1 2025 reduction was Acadia Pharmaceuticals, cutting an estimated $1.36M.
  • Birchview Capital fully exited Sarepta Therapeutics in Q1 2025, selling an estimated $426K.
  • Birchview Capital's ten largest holdings make up 66% of its $115M portfolio in Q1 2025.
  • Birchview Capital opened 4 new positions and closed 4 in Q1 2025.
  • Birchview Capital's portfolio value fell 6.3% quarter-over-quarter to $115M.

Based on Birchview Capital's 13F filing for Q1 2025, filed 15 May 2025.